Algorae Pharmaceuticals Limited
1AI.ASXHealth Care
Pharmaceutical development and commercial
Market Data
$0.012
+0.0%$24.3M
-100000.0x
$-0.001
0.00%
-0.2%
Latest Earnings
Half Year Report and Appendix 4D
27 February 2026
Algorae Pharmaceuticals (ASX: 1AI) reported its HY results for the six months ended 31 December 2025, posting a net loss of $863,912 — a 32.4% increase in losses compared to the prior corresponding period — driven by higher R&D spend on AlgoraeOS and pre-clinical programs, elevated share-based payments, and a foreign exchange loss. Revenue of $33,815 comprised solely of interest income (down 43.6% pcp) as the commercialisation arm, AlgoraeRx, had not yet generated product sales. On the positive side, the company made meaningful strategic progress, executing licensing agreements with Sakar Healthcare, Dr. Reddy's, and Cadila, while also launching AlgoraeOS v2 and securing a post-period A$3.0M working capital facility with ScotPac. Key points: AlgoraeOS v2 launched in November 2025, trained on 5.5M+ drug-inhibition records; outperformed Google DeepMind's TxGemma-27B-Predict in benchmarks.; Positive independent preclinical validation of AlgoraeOS v1 conducted by Peter MacCallum Cancer Centre, supporting the platform's drug-combination prioritisation capability.; Three commercial licensing/distribution agreements executed during the period: Sakar Healthcare (5 oncology generics), Dr. Reddy's (capecitabine), and Cadila Pharmaceuticals (cardiovascular/metabolic generics, LSA executed Feb 2026).
Recent Announcements
Half Year Report and Appendix 4D
Algorae Pharmaceuticals (ASX: 1AI) reported its HY results for the six months ended 31 December 2025, posting a net loss of $863,912 — a 32.4% increase in losses compared to the prior corresponding period — driven by higher R&D spend on AlgoraeOS and pre-clinical programs, elevated share-based payments, and a foreign exchange loss. Revenue of $33,815 comprised solely of interest income (down 43.6% pcp) as the commercialisation arm, AlgoraeRx, had not yet generated product sales. On the positive side, the company made meaningful strategic progress, executing licensing agreements with Sakar Healthcare, Dr. Reddy's, and Cadila, while also launching AlgoraeOS v2 and securing a post-period A$3.0M working capital facility with ScotPac. Key points: AlgoraeOS v2 launched in November 2025, trained on 5.5M+ drug-inhibition records; outperformed Google DeepMind's TxGemma-27B-Predict in benchmarks.; Positive independent preclinical validation of AlgoraeOS v1 conducted by Peter MacCallum Cancer Centre, supporting the platform's drug-combination prioritisation capability.; Three commercial licensing/distribution agreements executed during the period: Sakar Healthcare (5 oncology generics), Dr. Reddy's (capecitabine), and Cadila Pharmaceuticals (cardiovascular/metabolic generics, LSA executed Feb 2026).
Get real-time alerts for 1AI
Receive AI-powered earnings summaries and instant notifications when Algorae Pharmaceuticals Limited releases results.
Register Free